Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

Opinion
Video

Panelists discuss how anti-VEGF therapies have dramatically improved visual outcomes in patients with age-related macular degeneration and diabetic macular edema over the past decade. Key challenges persist, including treatment burden, adherence, and identifying optimal dosing regimens for individual patients.

Video content above is prompted by the following:

  • Anti-VEGF treatments have been available for age-related macular degeneration and diabetic macular edema for over a decade. Can you discuss how they have impacted patient outcomes and what barriers remain to achieving optimal results?

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Related Content
A movie theatre with empty seats. The screen has reels of film negatives, with a blue tint, and the words "Coming Soon" in large yellow letters. Image credit: Created with Canva. Components via Photology2000 and Ron Lach, Pexels.

EURETINA industry previews: Beacon Therapeutics, Nanoscope Therapeutics and Valitor

Kassi Filkins
September 3rd 2025
Article
PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

September 3rd 2025
Podcast
European Union flags outside the Berlaymont building in Brussels, Belgium, the headquarters of the European Commission. Concept image for ZEISS Medical Technology CE Mark CIRRUS PathFinder AI. Image credit: © olrat – stock.adobe.com

European Commission issues CE mark for Zeiss CIRRUS PathFinder AI tool

Hattie Hayes
September 3rd 2025
Article
PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

September 3rd 2025
Podcast
A surgical tray sits on a dirt road. There are visible scalpels and other metal tools. Concept image for ocular trauma, conflict and combat zones, eye surgery and emergency ophthalmology in low-resource, high-conflict regions or war zones. Created by Jennifer Toomey using Adobe Firefly AI.

Clinicians keep their eyes on wartime ocular trauma

Oksana Vitovska, MD; Sibylle Scholtz, PhD;Hattie Hayes
September 3rd 2025
Article
A glass building with a sign reading "RESERVE BANK." There are $100 Australian bank notes superimposed over the image. Concept image for Mirugen funding, cell reprogramming biologic biotech business of retina care news. Image credit: ©Rose Makin – stock.adobe.com

Australian biotech firm Mirugen secures major funding for cell reprogramming therapy

Hattie Hayes
September 3rd 2025
Article
© 2025 MJH Life Sciences

All rights reserved.